The California Stem Cell Report

Share this post

User's avatar
The California Stem Cell Report
It's a Tale of Ticking Clocks and Risky Endeavors
Copy link
Facebook
Email
Notes
More

It's a Tale of Ticking Clocks and Risky Endeavors

The bubble baby treatment, Orchard and CIRM's future

David Jensen's avatar
David Jensen
Mar 02, 2022
∙ Paid

Share this post

User's avatar
The California Stem Cell Report
It's a Tale of Ticking Clocks and Risky Endeavors
Copy link
Facebook
Email
Notes
More
Share
Google graphic

Somewhat lost in the recent news about UCLA’s “bubble  baby” gene therapy cure is the current state of affairs at the London company that abandoned the treatment nearly two years ago. 

The firm is Orchard Therapeutics PLC, a publicly traded enterprise that was founded in 2015.  One of its foundational products was to be a gene therapy for A…

Keep reading with a 7-day free trial

Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 David Jensen
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More